Karlsson Omar, Rajpal Sunil, Johri Mira, Kim Rockli, Subramanian S V
Duke University Population Research Institute, Duke University, 140 Science Dr, Durham, NC, 27710, USA.
Centre for Economic Demography, School of Economics and Management, Lund University, P.O. Box 7083, Lund, 220 07, Sweden.
J Epidemiol Glob Health. 2024 Dec;14(4):1490-1503. doi: 10.1007/s44197-024-00294-6. Epub 2024 Sep 19.
Not receiving a DPT-containing vaccine in early childhood indicates an absence of routine immunization, which puts children at an elevated risk of mortality, morbidity, and worse human development over the life course. We estimated the percentage of children 12-35 months who did not receive a dose of DPT-containing vaccine (termed zero-dose children) using household surveys from 81 low- and middle-income countries conducted between 2014 and 2023. For 68 countries with more than one survey (with the earlier survey conducted 2000-2013), we estimated the average annual percentage point change in prevalence of zero-dose children between the earliest and latest surveys. We also explored the association of zero-dose prevalence with postneonatal and child mortality, health expenditure, and Gavi-eligibility. Overall, 16% of children in our pooled sample had not received a dose of DPT-containing vaccine. There was a 0.8% point decline in zero-dose prevalence per year on average across the period studied. A single percentage point average annual decline in zero-dose prevalence was associated with an average annual decrease of 1.4 deaths in the postneonatal and childhood period per 1000 live births. Gavi-eligible countries had a much faster decline in zero-dose prevalence than other countries. Large gains have been made in reducing the percentage of children who did not receive a DPT-containing vaccine. Efforts to reduce the number of zero-dose children should focus on countries with high prevalence to achieve the Immunization Agenda 2030. Healthcare spending could be prioritized so that the prevalence of zero-dose children is reduced.
幼儿期未接种含百白破疫苗表明缺乏常规免疫,这会使儿童在整个生命过程中面临更高的死亡、发病风险以及更差的人类发育状况。我们利用2014年至2023年间对81个低收入和中等收入国家进行的家庭调查,估算了12至35个月大儿童中未接种一剂含百白破疫苗(称为零剂次儿童)的比例。对于有不止一次调查(最早一次调查在2000年至2013年进行)的68个国家,我们估算了最早和最新调查之间零剂次儿童患病率的年均百分点变化。我们还探讨了零剂次患病率与新生儿后期及儿童死亡率、卫生支出和符合全球疫苗免疫联盟(Gavi)资助条件之间的关联。总体而言,我们汇总样本中的16%儿童未接种含百白破疫苗。在所研究期间,零剂次患病率平均每年下降0.8个百分点。零剂次患病率年均下降一个百分点与每1000例活产新生儿后期及儿童期平均每年减少1.4例死亡相关。符合Gavi资助条件的国家零剂次患病率下降速度比其他国家快得多。在降低未接种含百白破疫苗儿童比例方面已取得了巨大进展。减少零剂次儿童数量的努力应聚焦于患病率高的国家,以实现2030年免疫议程。可优先安排医疗保健支出,以便降低零剂次儿童的患病率。